Seaside Therapeutics

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Seaside Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 8 completed top decile by trial count

Seaside Therapeutics: 12 sponsored US clinical trials, none currently recruiting.

Seaside Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 4 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Fragile X Syndrome, with 1 trials.

Top-decile sponsor footprint

Seaside Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 6/100

8 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (66.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

TERMINATED Phase 3

An Open Label Extension Study in Subjects With Fragile X Syndrome

NCT01555333
TERMINATED Phase 3

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

NCT01706523
COMPLETED Phase 3

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome

NCT01325220
COMPLETED Phase 3

Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome

NCT01282268
COMPLETED Phase 2

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

NCT01288716
TERMINATED Phase 2

An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders

NCT01064973
TERMINATED Phase 2

An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome

NCT01013480
COMPLETED Phase 1

A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

NCT00965432
COMPLETED

Biomarker and DNA Collection in Subjects Participating in Protocol 22003

NCT00892580
COMPLETED Phase 2

Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

NCT00846547
COMPLETED

Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

NCT00823368
COMPLETED Phase 2

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

NCT00788073

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 5
Phase 3 4

Therapeutic Areas

Fragile X Syndrome 1

How the Seaside Therapeutics archive is shaped

12 indexed studies, none listed as recruiting (0% open); 8 completed (67%).

Phase mix: 4 late (III/IV) vs 6 early (I/II) (balanced across stages).

Top condition: Fragile X Syndrome (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Seaside Therapeutics: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Seaside Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Seaside TherapeuticsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Seaside Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Seaside Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Seaside Therapeutics page

12 registered trials is a research-attention snapshot, not an endorsement of Seaside Therapeutics or any single study.

  • None of Seaside Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Fragile X Syndrome is the condition Seaside Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Fragile X Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Seaside Therapeutics pipeline card: 12 registered trials from official public datasets.Report a data error.